130273-99-3
Chemical Structure
KP-10614
- CAS No.: 130273-99-3
- Formula:C23H32O4
- Molecular Weight:372.50
IUPAC Name: (Z)-5-((3aS,5R,6R,6aS)-5-hydroxy-6-((3S,4S,E)-3-hydroxy-4-methylnon-1-en-6-yn-1-yl)-1,3a,4,5,6,6a-hexahydropentalen-2-yl)pent-4-enoic acid
InChIKey: LHDZAKZWZVBVTK-RISFQUNISA-N
SMILES: CCC#CC[C@H](C)[C@H](O)/C=C/[C@@H]1[C@]2([H])[C@@](C[C@H]1O)([H])C=C(C2)/C=C\CCC(O)=O
Biological Activity: KP-10614 is a potent, orally active platelet aggregation inhibitor. KP-10614 inhibits platelet aggregation induced by ADP with IC50 of 1 nM. KP-10614 causes dose-dependent inhibition of ex vivo platelet aggregation in rats. KP-10614 shows antithrombotic effects in various thrombosis models. KP-10614 can be used for thrombotic diseases research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
KP-10614 | KP-10614 is a potent, orally active platelet aggregation inhibitor. KP-10614 inhibits platelet aggregation induced by ADP with IC50 of 1 nM. KP-10614 causes dose-dependent inhibition of ex vivo platelet aggregation in rats. KP-10614 shows antithrombotic effects in various thrombosis models. KP-10614 can be used for thrombotic diseases research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
